A biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. CNS’ lead product candidate, Berubicin, is Read more…
NORTH CHICAGO, Ill., May 19, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17). “We are advancing discovery and innovation Read more…
Multiple Myeloma (MM) is a heterogeneous cancer disease comprised of various distinct subtypes and accounts for nearly 20 percent of deaths caused by all blood related diseases. Treatment of this disease has improved over the last decades, however some patients continue to experience multiple relapses, which contribute to premature deaths. Read more…
Data from a new study by researchers at Fox Chase Cancer show that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutations. According to lead author Margaret von Mehren, MD, chief of the Division of Sarcoma Medical Read more…
The IMF-funded iStopMM study (Iceland Screens, Treats, or Prevents Multiple Myeloma) is the largest study of its kind, with a record-setting 80,759 participants. A cancer of the bone marrow plasma cells, multiple myeloma is always preceded by a condition called MGUS, in which an abnormal protein appears in the blood. Read more…
The CIBMTR® (Center for International Blood and Marrow Transplant Research®) announces the launch of a large observational study, done in collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to understand the safety, efficacy, and durability of responses to COVID-19 vaccines in patients with hematological malignancies and non-malignant Read more…
An American Cancer Society (ACS) review of cancer prevention and early detection measures for 2018 and 2019 in the United States shows mixed progress. Smoking prevalence during this time was at an historic low, partly because most people who ever smoked have quit. But obesity rates remained high, and cancer Read more…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Phase 3 RATIONALE 309 trial of its anti-PD-1 antibody tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal Read more…
Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as Read more…
Using donated umbilical cord blood, researchers from City of Hope National Medical Center in Los Angeles created an off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapy that prolonged life with minimal side effects in a mouse model of metastatic human pancreatic cancer. The novel therapy, which targets prostate Read more…